Literature DB >> 8703830

Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation.

P Anderlini1, D Przepiorka, Y Huh, J Lauppe, P Miller, J Sundberg, D Seong, R Champlin, M Körbling.   

Abstract

Seventy-seven normal donors underwent leukapheresis for peripheral blood progenitor cell collection beginning on day 4 (n = 45) or day 5 (n = 32) of filgrastim mobilization (12 micrograms/kg/d). The two groups were comparable for age, weight, blood volumes processed during leukapheresis and target CD34+ cell dose to be collected. The day 5 schedule allowed a more consistent achievement of the target cell dose with one apheresis (P = 0.005) and resulted in the initial collection of a significantly larger number of CD34+ cells (P = 0.009). There was no statistically significant difference in the leukapheresis yield of lymphoid subsets and natural killer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703830     DOI: 10.1046/j.1365-2141.1996.d01-1747.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.

Authors:  D Karpova; K Dauber; G Spohn; D Chudziak; E Wiercinska; M Schulz; A R Pettit; J P Levesque; B Romagnoli; K Patel; E Chevalier; K Dembowsky; H Bonig
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

Review 2.  Mobilized peripheral blood: an updated perspective.

Authors:  Darja Karpova; Michael P Rettig; John F DiPersio
Journal:  F1000Res       Date:  2019-12-20

3.  Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization.

Authors:  Patricia A Shi; Luis M Isola; Janice L Gabrilove; Erin L Moshier; James H Godbold; Lorraine K Miller; Paul S Frenette
Journal:  Stem Cell Res Ther       Date:  2013-03-20       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.